Temple University

Philadelphia Health and Education Corporation

Other

Inkine Pharmaceutical Company, Inc.

Proplex Technologies, LLC

George P Tuszynski

Frank N Chang

Taffy J Williams

Phu T Duong

Mahesh C Sharma

Paul Actor

John F Wong

Jeff Yang

Solomon Luo

A method for detecting cells having granules expressing G protein coupled receptor-associated sorting protein 1 (GASP-1) or a fragment thereof is provided. The detection method may comprise: (a) contacting the cells with an effective amount of a binding protein, wherein the binding protein comprises an antigen binding fragment that specifically binds GASP-1; and (b) identifying cells having granules bound to the binding protein. The GASP-1 granules may be in the cytosol or on the surface of the cells. Also provided are methods for producing T-cells comprising a chimeric antigen receptor, anti-GASP-1 antibody or a bi-specific binding protein. Further provided are methods for treating GASP-1-mediated to disease or inactivating exosomes, microvesicles or oncosomes.

Binding proteins and chimeric antigen receptor T cells targeting GASP-1 granules and uses thereof

An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from 'redoxin proteins' selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.

Stabilized peptide fragments from nucleoredoxin X1 and uses thereof

Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Administration of angiocidin for arresting the growth of a tumor cell

Methods for identifying disease-specific markers, in particular breast cancer markers, by electrophoretically separating serum albumin complexes in a biological sample on a membrane are provided. Electrophoretic separation profiles representing different diseases or different cancer stages can be produced, and used in the diagnosis, prognosis and treatment of these diseases. Methods for identification of a cancer peptide fragment comprising a cancer peptide motif are provided. Also provided are breast cancer and other cancer markers and antibodies that specifically recognize these markers.

Serum markers associated with early and other stages of breast cancer

A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.

G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker

Administration of angiocidin for the treatment of leukemia

Disease specific markers, in particular cancer markers, can be detected by electrophoretically separating proteins and protein complexes from a biological sample on a protein binding polymeric membrane in a low conductivity, water-miscible organic solvent buffer. Electrophoretic separation profiles representing different diseases can be produced, and used in the diagnosis or prognosis of these diseases.

Method for detecting disease markers

Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a compound which binds annexin II and a pharmaceutically acceptable vehicle and methods for identifying such compounds.

Methods and compositions for inhibiting angiogenesis

The present invention provides methods and compositions for treating cancer and chemotherapy-resistant cancers comprising a chemotherapeutic agent conjugated to or coadministered with a peptide.

Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

The present invention relates generally to polypeptides that mimic or inhibit the biological activity of thrombospondin, and particularly to polypeptides in retroinverso form. These polypeptides may be used for their biological and pharmaceutical applications such as: (a) inhibiting the invasive and metastatic activity of melanoma cells, (b) promoting and inhibiting cellular attachment to tissue culture flacks, (c) promoting wound healing, angiogenesis, and implant acceptance, (d) agents for anti-platelet aggregation, (e) agents for antimalarial activity, and (f) diagnostic reagents in different therapeutic applications, as well as other related areas.

Growing community of inventors

Pittsgrove, NJ, United States of America

George P Tuszynski